NL-OMON37212已完成不适用
Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur® - AER-2012
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age between 18 and 65 year
排除标准
- •A know or suspected allergy towards one of the components of the vaccine, i.e. chicken protein, polygeline, neomycin, chlorotetracyclin and amfotericine B.
- •History of serious allergic reactions
- •Use of medication to suppress immune response
- •A chronic disease that affects the immune system, systemic diseases such as SLE, ANCA associated vasculitis
- •Pregnancy or actual child wish (upon inquiry at the time of screening)
研究者
相似试验
进行中（未招募）
不适用
Antibodies against EBLV after immunization with Rabipurhealthy volunteersMedDRA version: 14.1Level: LLTClassification code 10069589Term: Rabies immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-002096-34-NLCrucell Holland B.V.
招募中
不适用
eutralizing antibodies and clinical isolates of human immunodeficiency viruses (HIV).HIV infectionJPRN-UMIN000004720Matsushita project, Center for AIDS Research, Kumamoto University60
招募中
不适用
Study for development of new treatment for antibody mediated rejection in organ transplantatioorgan failureJPRN-UMIN000030525Tokyo Women's Medical University41
招募中
不适用
The study of ANCA for efficacy of biologics therapy in patients with ulcerative colitislcerative colitisJPRN-UMIN000043883Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital200
招募中
不适用
Serological screening and metabolic analysis for evaluation of the immune response to SARS-CoV2 (COVID-19)COVID-19DRKS00022292niversitätsklinikum Freiburg Klinik für Innere Medizin I250